ArticleMedicine2025
Association of lipidome with senility and the mediated effect of metabolites: A Mendelian randomization study.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The aim of this study was to assess the causal effects of lipidome on senility and the mediated effects of metabolites by Mendelian randomization (MR). Lipidome, metabolites, and senility datasets were acquired in genome-wide association study, and single nucleotide polymorphisms were screened according to the underlying assumptions of MR. Subsequently, inverse variance-weighted was used as the primary method to analyze the causal effect of lipidome on senility and the mediated effect of metabolites. Finally, MR-Egger intercept, Cochran Q, and leave-one-out sensitivity analysis were used to assess horizontal pleiotropy, heterogeneity, and robustness of the results, respectively. The MR analysis showed that phosphatidylcholine (PC) (18:2_0:0) increased genetic susceptibility to senility by reducing X-17690 levels (mediated proportion 7.36%, P = .033); PC (16:0_22:5) (mediated proportion 29.20%, P < .001) and PC (18:0_22:5) (mediated proportion 25.60%, P < .001) increased genetic susceptibility to senility by reducing dimethylglycine levels. Additionally, phosphatidylethanolamine (PE) (18:0_20:4) decreased genetic susceptibility to senility by increasing linoleoyl-arachidonoyl-glycerol (18:2/20:4) [1] levels (mediated proportion 11.30%, P < .001); PE (18:0_20:4) reduced genetic susceptibility to senility by reducing the glucose to N-palmitoyl-sphingosine (d18:1 to 16:0) ratio (mediated proportion 11.20%, P = .002). These results were free of horizontal pleiotropy and heterogeneity and were robust. Our findings revealed 5 pathways for lipidome regulating senility through metabolites. Lipidome components, including PC (18:2_0:0), PC (16:0_22:5), PC (18:0_22:5), and PE (18:0_20:4), as well as metabolites such as X-17690, linoleoyl-arachidonoyl-glycerol (18:2/20:4) [1], dimethylglycine, and glucose to N-palmitoyl-sphingosine (d18:1 to 16:0) ratio, may play an important role in the regulation of senility.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.